Prope tolerance with alemtuzumab.

Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society

Volumn 11, Issue 3, 2005, Pages 361-363

  Calne, Roy Y ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CANCER ANTIBODY; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

FOLLOW UP; GRAFT REJECTION; HUMAN; IMMUNOLOGY; LIVER TRANSPLANTATION; NOTE; POSTOPERATIVE COMPLICATION; TIME;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; TIME FACTORS;

EID: 21244478162     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1002/lt.20366     Document Type: Note

References (0)